Effect of Bezafibrate on Soluble Adhesion Molecules and Platelet Activation Markers in Patients With Connective Tissue Diseases and Secondary Hyperlipidemia
Free accessOtherFirst published online April, 2001
Effect of Bezafibrate on Soluble Adhesion Molecules and Platelet Activation Markers in Patients With Connective Tissue Diseases and Secondary Hyperlipidemia
We evaluated the plasma concentrations of soluble adhesion molecules, platelet activation markers, and platelet-derived microparticles (PMPs) in patients with connective tissue diseases who had secondary hyperlipidemia caused by long-term steroid administration (n = 22) before and after treatment with bezafibrate. There were differences in levels of platelet. activation markers both before and after treatment (platelet CD62p: 15.11 ± 2.03 vs 10.38 ± 8.53%. P < 0.05; ptatetet CD63: t2.i2 ± 9.17 vs 9.90 ± 7.20%, P < 0.05). There were also differences in the levels of PMPs and soluble adheSion molecules both before and after treatment (PMP: 514 ± 273 vs 401 ± 201 /104 platelet, P < 0.05; soluble vascular cell adhesion molecule-1 : 724 ± 191 vs 666 ± 157 ng/mL, P < 0.01). After 6 months of treatment, serum lipid concentrations were reduced by 9% for total cholesterol (TC) and 32% for triglyceride (TG). The level of PMPs, activated platelets, and soluble adhesion molecules were all significantly decreased after treatment with bezafibrate. These findings suggest that bezafibrate may be useful for inhibiting both PMP-dependent and -independent vascular damage in patients with connective tissue diseases complaining of secondary hyperlipidemia.
Lin RC, Snodgrass PJEffect of dexamathasone on 3-hydroxy 3-methyl glutaryl Coenzyme A reductase activity and cholesterol synthesis in rat liver. Biochim Biophys Acta1982;713:240.
2.
Stern MP, Kolterman OG, Fries JF, et al. Adrenocortical steroid treatment of rheumatic disease. Arch Int Med1973; 132:97.
3.
Koizumi F., Fukase M., Wakaki K.Clinicopathological study of coronary arterial lesions in 60 cases with systemic lupus erythematosus. Clin Immunol1982;14:406.
4.
Kagawa H.Okubo S.Yasunaga K.Plasma coagulation and fibrinolysis parameters in patients with collagen diseases, and analysis of the multimeric structure of von Willebrand factor (vWF). Int J Hematol1991;54:429.
5.
Angles-Cano E., Sultan Y., Cluvel J-P.Predisposing factors to thrombosis in systemic lupus erythematosus. Arthritis Rheum198225:1271.
6.
Rick ME, Hoyer LWHaemostatic disorders in systemic lupus erythematosus. Clin Rheum Dis1982;1:583.
7.
Kahaleh MBOsborn I., Leroy ECIncreased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scteroderma and in Raynaud's phenomenon. Ann Intern Med1981;94: 482.
8.
Murakami T., Komiyama Y., Masuda M., et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest1996;26:996.
9.
Sims PJ, Wiedmer T., Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem1989;264:17049.
10.
Nomura S., Komiyama Y., Matsuura E. et al. Participation of α 11b β3 in platelet microparticle generation by collagen plus thrombin. Haemostasis1996;26:31.
11.
Springer TAAdhesion receptors of the immune system. Nature1990:346:425.
12.
Bevilacqua MPEndothelial-leukocyte adhesion molecules. Ann Rev Immunol1993;1:767.
13.
Kling E., Bieg S., Boehme M., et al. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. J Clin Invest1993;71:299.
14.
Sfikakis PP , Charalambopoulos D., Vayioppulos G., et al. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol1994; 12:5.
15.
Janssen BA, Luqmani RA, Gordon C., et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis . Br J Rheumatol1994;33:1112.
16.
Miettinen T.Cholesterol balance and lipoprotein metabolism in man. Atheroscler Rev1986; 15: 113.
17.
Elinarsson K., Angelin B.Hyperlipoproteinemia, hypolipidemic treatment and gallstones disease. Atheroscler Rev1986 ;15:67.
18.
Eisenberg S. , Gavish D., Oschry Y., et al. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafthrate treatment. J Clin Invest1984;74: 470.
19.
Sullivan DR , Ktuijswijk Z.West CE, et al. Determination of serum triglyceride by an accurate enzymatic method not affected by free glycerol. Clin Chem1985;31:1227.
20.
Richmond W.Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chein1973;19:1350.
21.
Miyazaki Y., Nomura S., Miyake T., et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood1996;88:3456.
22.
Nomura S., Suzuki M., Katsura K., et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis1995; 116:235.
23.
Miyake T., Nomura S., Komiyama Y. et al. Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Thromb Haemost1997;78:902.
24.
Nomura S., Nagata H., Oda K., et al. Effects of EDTA on membrane glycoprotein IIb-IIIa complex: analysis using flow cytometry. Thromb Res1987;47:47.
25.
Yanabu M., Ozaki Y., Nomura S., et al. Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monaclonal antibody. Blood1997;89:1590.
26.
Chobanian AVSingle risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hyper hypercholesterolemia coexist. Hypertension1991;18:130.
Sims PJ, Wiedmer T., Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem1989;264:17049.
29.
Zwaal Rfa, Comfurius P., Bevers EMPlatelet procoagulant activity and microvesicle formation: its putative role in hemostasis and thrombosis. Biochim Biophys Acta1992; 1180: 1.
30.
Tans G., Rosing J., Thomassen MC, et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticle'.s. Blood1991-177:2641.
31.
Dahlback B. , Wiedmer T., Sims PJBinding of anticoagulant vitamin K-dependent protein S to platelet-derived micropartictes. Biochemistry1992,31:12769.
32.
Gilbert GE, Sims PJ, Wiedmer T., et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem1991;266:17261 .
33.
Comfurius P. , Senden Jmg, Tilly Rhj, et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of amminophosphotipid translocase . Biochim Biophys Acta1990;1026:153.
34.
Jy W., Horstmann LL, Arce M., et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med1992; 119:334.
35.
Hailer S., Pogarell O., Keller C., et al. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypcrchoiesterotemia . Arzneimittelforschung1996;46:879.
36.
Spieker LE, Noll G., Hannak M., et al. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol2000;35:361.
37.
Barry OP, Pratico D., Lawson JA, et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest1997;99:2118.
